Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJDU5S)

Drug Name

quinazoline deriv. 1 Drug Info

Synonyms

Aurora Kinase Inhibitor II; quinazoline deriv 1; 331770-21-9; CHEMBL382590; -Benzamidoanilino)-6,7-dimethoxyquinazoline; N-{4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl}benzamide; N-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]benzamide; Anilinoquinazoline1; K00590a; CBiol_002061; 4-(4'-Benzamidoanilino)-6,7-dimethoxyquinazoline; GTPL5930; SCHEMBL1066538; AC1O7M16; CTK8E8821; BDBM12403; DTXSID00425012; MolPort-044-561-446; Bio1_000347; ZINC590935; HMS3229A17; Bio1_001325; Bio1_000836; IN1528; CCG-206735

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 6610278
CAS Number: CAS 331770-21-9
TTD Drug ID: DMJDU5S

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Aurora B messenger RNA (AURKB mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PHA-739358	DMGYBZI	Prostate cancer	2C82.0	Phase 2	[3]
Indirubin-3'-monoxime	DMLRQH0	Discovery agent	N.A.	Investigative	[4]
SU 6656	DMF1P6W	Discovery agent	N.A.	Investigative	[5]
6-bromoindirubin-3-oxime	DM12WYV	Discovery agent	N.A.	Investigative	[4]
7-fluoroindirubin-3-oxime	DMQD34N	Discovery agent	N.A.	Investigative	[4]
PMID21742770C1	DME3JMH	Discovery agent	N.A.	Investigative	[6]
Indirubin-3-acetoxime	DM3UR1E	Discovery agent	N.A.	Investigative	[4]
CGP-57380	DMFPOUC	Discovery agent	N.A.	Investigative	[5]
PMID20855207C25	DMNEB6J	Discovery agent	N.A.	Investigative	[7]
Indirubin-3-methoxime	DMZ5ODC	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Aurora kinase C (AURKC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PHA-739358	DMGYBZI	Prostate cancer	2C82.0	Phase 2	[3]
ABT-348	DMMZOYN	Haematological malignancy	2B33.Y	Phase 2	[8]
HPP-607	DM5VSZR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
AMG 900	DMASGXJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
SNS-314	DMAC5F2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
GSK1070916	DMXRPT6	Advanced solid tumour	2A00-2F9Z	Phase 1	[12]
GSK1070916A	DMCJUI9	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
MK-6592	DMB5NOI	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[13]
Indirubin-3'-monoxime	DMLRQH0	Discovery agent	N.A.	Investigative	[4]
SU 6656	DMF1P6W	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aurora B messenger RNA (AURKB mRNA)	TT9RTBL	AURKB_HUMAN	Inhibitor	[2]
Aurora kinase C (AURKC)	TTLYXIT	AURKC_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5930).
2	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
3	Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4.
4	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
5	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
6	A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
7	Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43.
8	Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
10	Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
11	SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
12	Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
13	Clinical experience with aurora kinase inhibitors: a review. Oncologist. 2009 Aug;14(8):780-93.